Loading profile
Loading sourced facts.
01 Finding sources
02 Reading evidence
03 Filing the card
Loading profile
01 Finding sources
02 Reading evidence
03 Filing the card
Amyris uses precision fermentation to convert plant sugars into sustainable specialty molecules for consumer product and industrial ingredient markets.
Raised $1.7B across disclosed rounds.[5]
Post-IPO Equity closed December 2022, led by Foris Ventures, LLC.[7]
post-money valuation is not publicly disclosed.
Named investors include Foris Ventures, LLC, Vivo Capital LLC, Jefferies LLC, Cowen and Company LLC, Oppenheimer & Co. Inc., H.C. Wainwright & Co..[1][2][7][8][9]
Kathy Fortmann, Chief Executive Officer[4][10][11][12][13][14][16]
Sunil Chandran, Chief Technology Officer[4][10][11][12][13][14][16]
Lisa Roessler, Chief Commercial Officer[4][10][11][12][13][14][16]
Adam Blaziak, Chief Operations Officer[4][10][11][12][13][14][16]
Han Kieftenbeld, Chief Financial Officer (as of 2020)[4][10][11][12][13][14][16]
Jul 2026 · nasdaq.com
reported
Amyris uses precision fermentation to convert plant sugars into sustainable specialty molecules for consumer product and industrial ingredient markets.
Ask for one referenceable production customer.
Not a recommendation. The first thing this ledger cannot answer.
Brian Edquist, SVP, Portfolio Management & Computing[4][10][11][12][13][14][16]
John Hung, Director of Technology Partnerships[4][10][11][12][13][14][16]
Adam Meadows, Director of Data Science[4][10][11][12][13][14][16]
Kevin George, Director of Automated Strain Engineering[4][10][11][12][13][14][16]
Ginkgo Bioworks · ginkgobioworks.com · Same buyer (CPG and industrial partners seeking bio-manufactured ingredients), same job to be done (strain engineering and fermentation scale-up), and named together in market maps as competing synthetic biology platforms.[5]
Zymergen · zymergen.com · Same buyer (industrial and CPG partners), same workflow (strain engineering for novel molecules), and named together in talent flows and market maps.[5]
Codexis · codexis.com · Same buyer (industrial chemical and pharma partners seeking bio-catalysis), same budget line (bio-based ingredient R&D and manufacturing), and listed as competitor in enrichment data.[5]
Gevo · gevo.com · Same buyer (industrial chemical and fuel markets), same workflow (fermentation of sugars into hydrocarbon molecules), and listed as competitor in enrichment data.[5]
The customer proof is company-sourced only. No independent source in this ledger confirms it.[4]
Ask for one referenceable production customer.
Not a recommendation. The first thing this ledger cannot answer.
Filled in the side panel for invited readers. This card carries sourced facts only.
Jul 2026 · prnewswire.com
company
Jul 2026 · prnewswire.com
company